ES3009563T3 - Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels - Google Patents

Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels Download PDF

Info

Publication number
ES3009563T3
ES3009563T3 ES18865483T ES18865483T ES3009563T3 ES 3009563 T3 ES3009563 T3 ES 3009563T3 ES 18865483 T ES18865483 T ES 18865483T ES 18865483 T ES18865483 T ES 18865483T ES 3009563 T3 ES3009563 T3 ES 3009563T3
Authority
ES
Spain
Prior art keywords
amb
asl
cholesterol
patient
epithelia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18865483T
Other languages
English (en)
Spanish (es)
Inventor
Martin D Burke
Katrina A Muraglia
Rajeev S Chorghade
Michael J Welsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation
University of Illinois System
Original Assignee
University of Iowa Research Foundation
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation, University of Illinois System filed Critical University of Iowa Research Foundation
Application granted granted Critical
Publication of ES3009563T3 publication Critical patent/ES3009563T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES18865483T 2017-10-11 2018-10-11 Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels Active ES3009563T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762570795P 2017-10-11 2017-10-11
PCT/US2018/055435 WO2019075214A2 (en) 2017-10-11 2018-10-11 INDEPENDENT RESCUEING OF THE GENOTYPE OF CYSTIC FIBROSIS WITH BICARBONATE CHANNELS WITH SMALL MOLECULES

Publications (1)

Publication Number Publication Date
ES3009563T3 true ES3009563T3 (en) 2025-03-27

Family

ID=66100102

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18865483T Active ES3009563T3 (en) 2017-10-11 2018-10-11 Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels

Country Status (10)

Country Link
US (3) US12090164B2 (enExample)
EP (1) EP3694526B1 (enExample)
JP (2) JP7355335B2 (enExample)
AU (2) AU2018348214C1 (enExample)
CA (1) CA3076246A1 (enExample)
DK (1) DK3694526T3 (enExample)
ES (1) ES3009563T3 (enExample)
FI (1) FI3694526T3 (enExample)
PT (1) PT3694526T (enExample)
WO (1) WO2019075214A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3694526T (pt) 2017-10-11 2025-01-20 Univ Illinois Resgate independente do genótipo da fibrose quística com canais de bicarbonato de moléculas pequenas
IL315719A (en) 2022-03-21 2024-11-01 Univ Illinois Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals
WO2025019806A2 (en) * 2023-07-19 2025-01-23 The Board Of Trustees Of The University Of Illinois Restoring physiology with small molecule mimics of missing proteins
EP4780466A1 (en) * 2023-09-20 2026-07-29 The Board Of Trustees Of The University Of Illinois Additive effects for molecular prosthetcs and cftr modulators in cf epithelia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
AU2003304204B2 (en) * 2002-10-29 2009-12-24 Insmed Incorporated Sustained release of antiinfectives
TWI249408B (en) 2003-12-10 2006-02-21 Ind Tech Res Inst New antifungal formulation and manufacturing method thereof
CN101014322A (zh) * 2004-06-11 2007-08-08 吉藤德拉·纳提·维玛 盐水中富含固醇的添加两性霉素的混合层状脂质体及其制备方法
US8507441B2 (en) 2009-10-22 2013-08-13 University of Pittsburgh—Of the Commonwealth Systems of Higher Education Use of endostatin peptides for the treatment of fibrosis
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
JP6796581B2 (ja) * 2014-11-04 2020-12-09 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ ミッシングタンパク質の小分子模倣体を用いた生理機能の回復
ES2983639T3 (es) 2016-04-08 2024-10-24 The Board Of Trustees Of The Univ Illinois Restauración mediada por moléculas pequeñas de la fisiología de la superficie de las vías respiratorias en epitelios pulmonares humanos de fibrosis quística
US10960018B2 (en) * 2016-04-15 2021-03-30 The Uab Research Foundation Methods and compounds for stimulating read-through of premature termination codons
PT3694526T (pt) 2017-10-11 2025-01-20 Univ Illinois Resgate independente do genótipo da fibrose quística com canais de bicarbonato de moléculas pequenas

Also Published As

Publication number Publication date
US20250000886A1 (en) 2025-01-02
WO2019075214A3 (en) 2020-04-02
JP7355335B2 (ja) 2023-10-03
CA3076246A1 (en) 2019-04-18
FI3694526T3 (fi) 2025-02-06
US20250009775A1 (en) 2025-01-09
JP2020536859A (ja) 2020-12-17
AU2018348214B2 (en) 2024-08-08
EP3694526A4 (en) 2021-06-09
DK3694526T3 (da) 2025-02-03
JP2023126932A (ja) 2023-09-12
EP3694526A2 (en) 2020-08-19
US12090164B2 (en) 2024-09-17
US20200352970A1 (en) 2020-11-12
AU2024259758A1 (en) 2024-11-21
AU2018348214C1 (en) 2025-01-30
AU2018348214A1 (en) 2020-04-23
EP3694526B1 (en) 2024-12-04
WO2019075214A2 (en) 2019-04-18
PT3694526T (pt) 2025-01-20

Similar Documents

Publication Publication Date Title
Sun et al. Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis
Chennakesavulu et al. Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis
Xia et al. Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage
US6153217A (en) Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US20250000886A1 (en) Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels
US20090047336A1 (en) novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation
PT2079443E (pt) Formulações de inalação com dupla ação que proporcionam um perfil de libertação imediata e sustentada.
US11883528B2 (en) Compositions and methods for treating pulmonary edema or lung inflammation
EP3060198A1 (en) Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
Wang et al. Inhaled pulmonary surfactant biomimetic liposomes for reversing idiopathic pulmonary fibrosis through synergistic therapeutic strategy
US12419899B2 (en) Ion channel prosthetic compositions comprising lipid-coated crystals of amphotericin B
BR112020020127A2 (pt) Composição farmacêutica, método de tratamento de uma doença respiratória e método para reduzir o efeito colateral de um treprostinil inalado na via respiratória superior
CN115666552B (zh) 含有乙二胺四乙酸或其盐的艾日布林或其可药用盐脂质体
CN117897139A (zh) Bcl抑制剂的脂质体制剂
ES2983639T3 (es) Restauración mediada por moléculas pequeñas de la fisiología de la superficie de las vías respiratorias en epitelios pulmonares humanos de fibrosis quística
Anjum et al. Pulmonary targeted delivery of ivacaftor liposomes for F508 del-CFTR mutation mediated cystic fibrosis therapy
Chorghade Small molecule channels increase anion secretion and host defenses in cystic fibrosis airway epithelia: mechanistic studies and initial clinical translation
Cipolla Inhaled Liposomes
Mu et al. Decoupling efficacy from toxicity: Inhalable liposomal nintedanib for safe and effective treatment of pulmonary fibrosis
Duran-Lobato et al. Formulation of protein-loaded nanoparticles via freeze-drying
HK40046684A (en) Compositions and methods for treating pulmonary edema or lung inflammation